Releases
Current Releases
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in Asian patients with NSCLC
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
view complete archive
02/09/10 13:29 ET Quotes Delayed 20 minutes.